We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Saliva-Based PCR Assay Detects HIV Antibodies Earlier

By LabMedica International staff writers
Posted on 28 Feb 2018
An oral fluid-based test for human immunodeficiency virus (HIV) shows promise as a population-based screening tool. More...
According to its developers, the test is easier to collect than blood but yields results that are just as reliable.

In comparison to blood, which poses an infection risk to healthcare workers, oral fluid is not infectious. However, the problem with human saliva is it contains very few anti-HIV antibodies, the markers of HIV infection, and current oral fluid assays do not detect HIV as quickly or efficiently as blood tests.

Scientists at Stanford University (Stanford, CA, USA) have demonstrated how a new oral fluid test, the Antibody Detection by Agglutination– PCR (ADAP) technology, was able to successfully detect HIV at the early stages. The developers of ADAP analyzed how antibodies latch on to the HIV virus to create a more sensitive oral fluid test that was 1,000 to 10,000 times more sensitive than clinical enzyme-linked immunoassays in finding HIV antibodies. ADAP uses polymerase chain reaction (PCR), a technique often used to detect DNA, to find HIV antibodies.

The team used ADAP technology to accurately diagnose 22 individuals who participated in Alameda County Public Health Laboratory’s HIV screening program and had been diagnosed with HIV through other methods. Overall, it yielded 100% clinical sensitivity and 100% specificity for detecting these antibodies from oral fluids. The test also did not produce any false positive results in 22 additional individuals who were HIV negative. The enhanced analytical sensitivity enables this assay to correctly identify HIV-infected individuals otherwise missed by current oral fluid (OF) assays.

Carolyn R. Bertozzi, PhD, a professor of chemistry and the lead investigator of the study, said, “PCR is very sensitive, it can detect very low amounts of the target DNA, whereas techniques people use to detect proteins are far less sensitive. Our test brings the sensitivity of PCR to the testing of proteins, the HIV antibodies in oral fluid, more specifically. We can reset the standards for oral fluid diagnostic sensitivity, bringing it closer to that of blood tests but with convenience of oral fluid. ” The study was published on February 6, 2018, in the journal Proceedings of the National Academy of Sciences.

Related Links:
Stanford University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.